Literature DB >> 1988518

The human humoral immune response to Salmonella typhi Ty21a.

B D Forrest1, J T LaBrooy, L Beyer, C E Dearlove, D J Shearman.   

Abstract

The short-term kinetics and the effects of different dose regimens and formulations on the humoral immune response induced in human subjects by the live attenuated typhoid vaccine Salmonella typhi Ty21a were examined. Antibody responses in jejunal fluid and serum and by specific antibody production in vitro by peripheral blood lymphocytes to S. typhi lipopolysaccharide were determined. A short vaccination schedule of three doses of 10(11) live organisms over 5 days induced significantly greater intestinal IgA antityphoid antibody responses than did two comparable doses 21 days apart. The humoral immune response was dose dependent with 10(10) and 10(11) live organisms stimulating greater intestinal immune responses than did 10(11) killed organisms. No responses were evident with either 10(9) viable organisms or with an enteric-coated preparation. In the continued development and assessment of oral typhoid vaccines, the effects of different doses and formulations and the timing of sampling on the humoral immune response should be considered.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988518     DOI: 10.1093/infdis/163.2.336

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Indirect measurement of intestinal immune responses to an orally administered attenuated bacterial vaccine.

Authors:  B D Forrest
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

Review 2.  Antibodies and Protection in Systemic Salmonella Infections: Do We Still Have More Questions than Answers?

Authors:  Pietro Mastroeni; Omar Rossi
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

3.  Salmonella Paratyphi A Outer Membrane Vesicles Displaying Vi Polysaccharide as a Multivalent Vaccine against Enteric Fever.

Authors:  F Micoli; P Mastroeni; G Gasperini; R Alfini; V Arato; F Mancini; M G Aruta; P Kanvatirth; D Pickard; F Necchi; A Saul; O Rossi
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

4.  Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.

Authors:  Rezwanul Wahid; Marcela F Pasetti; Milton Maciel; Jakub K Simon; Carol O Tacket; Myron M Levine; Marcelo B Sztein
Journal:  Clin Immunol       Date:  2010-12-10       Impact factor: 3.969

5.  Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain.

Authors:  D Nardelli-Haefliger; J P Kraehenbuhl; R Curtiss; F Schodel; A Potts; S Kelly; P De Grandi
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

6.  Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans.

Authors:  Rezwanul Wahid; Raphael Simon; Shah J Zafar; Myron M Levine; Marcelo B Sztein
Journal:  Clin Vaccine Immunol       Date:  2012-04-04

Review 7.  Salmonella infection: Interplay between the bacteria and host immune system.

Authors:  Jonathan R Kurtz; J Alan Goggins; James B McLachlan
Journal:  Immunol Lett       Date:  2017-07-15       Impact factor: 3.685

8.  Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B.

Authors:  Rezwanul Wahid; Shah J Zafar; Monica A McArthur; Marcela F Pasetti; Myron M Levine; Marcelo B Sztein
Journal:  Clin Vaccine Immunol       Date:  2014-01-15

9.  Effect of parenteral immunization on the intestinal immune response to Salmonella typhi Ty21a.

Authors:  B D Forrest; J T LaBrooy; C E Dearlove; D J Shearman
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

10.  Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2.

Authors:  Vijayakumar Jawalagatti; Perumalraja Kirthika; Chamith Hewawaduge; Myeon-Sik Yang; Ji-Young Park; Byungkwan Oh; John Hwa Lee
Journal:  Mol Ther       Date:  2022-02-03       Impact factor: 12.910

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.